BI-3802 is a small molecule inhibitor that targets BCL6, a transcriptional repressor involved in the regulation of gene expression. Its primary application is in cancer research and therapy, particularly for treating B-cell lymphomas. By inhibiting BCL6, BI-3802 disrupts the protein's ability to promote cancer cell survival and proliferation, leading to the induction of apoptosis in malignant cells. This makes it a promising candidate for developing targeted therapies for cancers that rely on BCL6 for their growth and resistance to treatment. Additionally, BI-3802 is used in preclinical studies to better understand the role of BCL6 in oncogenesis and to explore its potential in combination with other anticancer agents.